钆夸曲兰在头颈和肝脏磁共振增强成像中的猪临床前剂量-效应研究
这项探索性前瞻性交叉研究在7头健康猪中比较了新型大环状钆对比剂钆夸曲兰(0.01、0.03、0.06 mmol Gd/kg)与钆布醇、钆特酸葡胺标准剂量(0.1 mmol Gd/kg)的信号增强效应。钆夸曲兰的相对信号增强随剂量线性增加(r²≥0.84),达到两种对照药标准剂量等效增强的剂量分别为0.031–0.039和0.040–0.049 mmol Gd/kg,提示其可能在低于0.05 mmol Gd/kg的剂量下有效。
要点
- 钆夸曲兰相对信号增强随剂量增加呈线性关系,多数结构r²≥0.84。
- 达到钆特酸葡胺标准剂量等效增强的钆夸曲兰剂量为0.031–0.039 mmol Gd/kg。
- 达到钆布醇标准剂量等效增强的钆夸曲兰剂量为0.040–0.049 mmol Gd/kg。
核心结论
- 钆夸曲兰的信号增强动力学与钆布醇和钆特酸葡胺相似,可能以低于0.05 mmol Gd/kg体重的剂量有效使用,且不依赖于所研究的解剖结构和脉冲序列。
研究设计与样本
- 探索性前瞻性交叉研究,7头健康猪,1.5T扫描仪,临床常规条件下行多期肝脏MRI(VIBE序列)及稳态头颈MRI(自旋回波与FLASH序列交替,注射后2至32分钟),以基线信号强度变化(相对信号增强)为评价指标。
诊断标准与关键数值
- 钆夸曲兰在稳态头颈MRI和多期肝脏MRI中所有解剖结构的相对信号增强均随剂量增加,与对比剂分布期和脉冲序列无关;线性回归总体拟合良好(r²≥0.84),但海绵窦自旋回波图像和肝静脉VIBE图像在最高钆夸曲兰剂量下相对信号增强不成比例地低(r²分别为0.78和0.48)。
局限性
- 探索性研究,样本为7头健康猪。
- 海绵窦自旋回波图像和肝静脉VIBE图像在最高钆夸曲兰剂量下相对信号增强不成比例地低(r²分别为0.78和0.48),线性模型拟合欠佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The objective of the study was to investigate the dose-response (signal enhancement) relationship and signal-enhancement kinetics of gadoquatrane in different anatomic regions employing different MRI pulse sequences. Gadoquatrane is a novel high-relaxivity, extracellular macrocyclic gadolinium-based contrast agent with tetrameric structure that has the potential to be used at lower Gd doses than long-established contrast agents.
MATERIALS AND METHODS: In this exploratory, prospective crossover study, 7 healthy pigs underwent contrast-enhanced MRI examinations with gadoquatrane (0.01, 0.03, and 0.06 mmol Gd/kg body weight) and standard doses (0.1 mmol Gd/kg) of 2 comparators, gadobutrol and gadoterate meglumine. MRI was performed on a 1.5T scanner under conditions typically used in clinical routine. Immediately after contrast-agent injection, multiphase liver MRI was done (VIBE sequence). Steady-state head-and-neck MRI followed (spin-echo and FLASH sequences alternating from 2 to 32 min after injection). Image evaluation was based on changes in signal intensity from baseline [relative signal enhancement (RSE)]. Simple linear regression analysis was used to investigate the relationship between RSE and gadoquatrane dose. The regression equations were used to estimate the comparator-equivalent doses of gadoquatrane.
RESULTS: The RSE achieved with gadoquatrane in steady-state head-and-neck MRI and multiphase liver MRI increased with dose in all anatomic structures examined, independent of the contrast-agent distribution phase and the pulse sequence employed. Linear regression analysis showed that generally a linear model fitted the dose-response data well ( r2 ≥ 0.84). However, in spin-echo images of the cavernous sinus and VIBE images of the hepatic vein, the areas with the strongest RSE, a disproportionately low RSE was seen with the highest gadoquatrane dose ( r2 of 0.78 and 0.48, respectively).RSE equivalent to the RSE achieved with gadoterate meglumine and gadobutrol at standard dose was achieved with gadoquatrane at doses between 0.031 to 0.039 mmol Gd/kg and 0.040 to 0.049 mmol Gd/kg, respectively. Largely parallel RSE-versus-time curves suggest similar signal-enhancement kinetics for gadoquatrane and the comparators.
CONCLUSIONS: The study suggests that gadoquatrane, which demonstrated signal-enhancement kinetics similar to those of gadobutrol and gadoterate meglumine, might be utilized effectively at a dose below 0.05 mmol Gd/kg body weight, independent of the anatomic structure investigated and the pulse sequence employed. Overall, the study supports and complements the results of the clinical dose-response study of gadoquatrane.
引用
- Jost G, Lohrke J, Hofmann BM, et al. Gadoquatrane in Contrast-enhanced Head-and-neck and Liver Magnetic Resonance Imaging: A Preclinical Dose-Response Study in Pigs. Invest Radiol. 2026. PMID: 41195752. doi:10.1097/RLI.0000000000001258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。